yttrium radioisotopes has been researched along with Lymphoma, Non-Hodgkin in 145 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (4.83) | 18.2507 |
| 2000's | 109 (75.17) | 29.6817 |
| 2010's | 23 (15.86) | 24.3611 |
| 2020's | 6 (4.14) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, I; Ito, T; Okada, M | 1 |
| Abedi, M; Hoeg, R; Lowsky, R; Othman, T; Richman, C; Tuscano, J | 1 |
| Iino, M; Sakamoto, Y; Sato, T | 1 |
| Au, KM; Hong, S; Lin, CP; Park, SI; Tripathy, A; Wagner, K; Wang, AZ | 1 |
| Bellò, M; Benevolo, G; Bisi, G; Boccomini, C; Botto, B; Castellino, A; Chiappella, A; Ciochetto, C; Freilone, R; Nicolosi, M; Orsucci, L; Passera, R; Pecoraro, C; Pregno, P; Vitolo, U | 1 |
| Belli, ML; Cicone, F; Cremonesi, M; Ferrari, ME; Guidi, C; Paganelli, G; Sarnelli, A; Wahl, R | 1 |
| Bodet-Milin, C; Cascini, GL; Cicone, F; Kolstad, A; Kraeber-Bodéré, F; Santo, G; Stokke, C | 1 |
| Buck, AK; Dreher, N; Einsele, H; Higuchi, T; Kraus, S; Rasche, L; Samnick, S; Serfling, SE; Werner, RA | 1 |
| Escorcia, FE; Viola, NT; White, JM | 1 |
| Handa, H; Higuchi, T; Ishida, F; Ishizaki, T; Koiso, H; Matsumoto, M; Mitsui, T; Murakami, H; Ogura, H; Saitoh, T; Sakura, T; Shimizu, H; Takizawa, M; Toyama, K; Tsukamoto, N; Tsushima, Y; Yokohama, A | 1 |
| Forero-Torres, A; Knox, SJ; LoBuglio, AF; Meredith, RF; Micallef, IN; Shah, JJ; Shen, S; Vaklavas, C | 1 |
| Allmer, C; Ansell, SM; Asmann, YW; Ballas, ZK; Colgan, JP; Gupta, M; Habermann, TM; Inwards, DJ; Johnston, PB; Link, BK; Maurer, MJ; Micallef, IN; Nowakowski, GS; Porrata, LF; Shanafelt, TD; Smith, BJ; Weiner, GJ; Wiseman, GA; Witzig, TE; Zent, CS | 1 |
| Bombardieri, E; Carlo-Stella, C; Chiesa, C; Cox, MC; Devizzi, L; Di Nicola, M; Gianni, AM; Guidetti, A; Maccauro, M; Magni, M; Matteucci, P; Passera, R; Ruella, M; Seregni, E; Tarella, C; Testi, A; Viviani, S | 1 |
| Hagenbeek, A | 2 |
| Ciolini, R; d'Errico, F; Del Gratta, A; Laganà, A; Paternostro, E; Pazzagli, F; Romei, C; Traino, AC | 1 |
| Akhlaghi, M; Gholipour, N; Jalilian, AR; Johari-Daha, F; Khalaj, A; Khanchi, AR; Sabzevari, O; Yavari, K | 1 |
| Goldenberg, DM; Kio, EA; Misleh, JG; Sharkey, RM; Tomblyn, MB; Wegener, WA; Witzig, TE | 1 |
| Kawashima, H | 1 |
| Boulahdour, H; Daguindau, E; Deconinck, E; Helias, P; Philippe, L; Puyraveau, M | 1 |
| Otte, A | 2 |
| Chen, J; Fani, M; Forrer, F; Lohri, A; Maecke, HR; Moldenhauer, G; Müller-Brand, J; Powell, P | 1 |
| Aricò, D; Cremonesi, M; Ferrari, M; Grana, CM; Mallia, A; Martinelli, G; Paganelli, G; Sansovini, M; Vanazzi, A | 1 |
| Dannaher, C; Greco, FA; Hainsworth, JD; Markus, TM; Rotman, R; Shipley, D; Spigel, DR; Thompson, D | 1 |
| Dreyling, M; Gisselbrecht, C; Gregory, SA; Hohloch, K; Tobinai, K | 1 |
| Bischof Delaloye, A; Dreyling, M; Hagemeister, F; Morschhauser, F; Rohatiner, A | 1 |
| Gianni, AM; Gisselbrecht, C; Nademanee, A; Nagler, A; Vose, J | 1 |
| Bischof Delaloye, A; Conti, PS; Gisselbrecht, C; Gregory, SA | 1 |
| Chen, J; Evens, AM; Gordon, LI; Hamilton, E; Helenowski, IB; Jovanovic, BD; Miller, RA; Miyata, S; Naumovski, L; Patton, D; Rosen, ST; Spies, S; Spies, WG; Variakojis, D; Winter, JN | 1 |
| Forero, A; Knox, SJ; Lobuglio, AF; Meredith, RF; Shah, JJ; Shen, S; Usrey, ME; Wiseman, GA | 1 |
| Bethge, WA; Bornhaeuser, M; Bunjes, D; Dittmann, H; Faul, C; Federmann, B; Kanz, L; Knop, S; Lange, T; Meisner, C; Stadler, M; Stelljes, M; Trenschel, R; Uharek, L; Vogel, W; von Harsdorf, S; Vucinic, V; Wulf, G | 1 |
| Bodet-Milin, C; Chatal, JF; Goldenberg, DM; Harousseau, JL; Horne, H; Huglo, D; Kirsch, CM; Kraeber-Bodéré, F; Kropp, J; Le Gouill, S; Meller, J; Morschhauser, F; Naumann, R; Petillon, MO; Pfreundschuh, M; Teoh, N; Trümper, LH; Wegener, WA | 1 |
| Baechler, S; Bochud, FO; Hobbs, RF; Jacene, HA; Sgouros, G; Wahl, RL | 1 |
| Gadaleta, CD; Goffredo, V; Paradiso, A; Ranieri, G | 1 |
| Buttiglieri, S; Carlo-Stella, C; Devizzi, L; Di Nicola, M; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Mariani, L; Miceli, R; Passera, R; Risso, A; Ruella, M; Tarella, C; Testi, A | 1 |
| Baurmann, H; Bethge, WA; Bornhauser, M; Bunjes, D; Dittmann, H; Faul, C; Federmann, B; Kanz, L; Stelljes, M; Trenschel, R; Vogel, W; von Harsdorf, S | 1 |
| Cilley, J; Evens, AM; Gallot, L; Gordon, LI; Larson, A; Patton, D; Rademaker, A; Roy, R; Spies, S; Variakojis, D; Winter, JN | 1 |
| Baechler, S; Boubaker, A; Dieudonné, A; Gardin, I; Hobbs, RF; Le Guludec, D; Lebtahi, R; Maurel, F; Sgouros, G; Wahl, RL | 1 |
| Carpaneto, A; Cicone, F; Coniglio, A; D'Arienzo, M; Delaloye, AB; Russo, E; Scopinaro, F | 1 |
| Cripe, L; Czuczman, MS; Emmanouilides, C; Flinn, IW; Gordon, LI; Multani, PS; Olejnik, T; Saleh, MN; White, CA; Wiseman, G; Witzig, TE | 1 |
| Ansell, SM; Habermann, TM; Ristow, KM; Wiseman, GA; Witzig, TE | 1 |
| Weiden, PL | 1 |
| Fisher, DR; Goldenberg, DM; Govindan, SV; Griffiths, GL; Sharkey, RM | 1 |
| Dewald, G; Gordon, LI; Kent, SA; Multani, P; Nabhan, C; Peterson, LA; Tallman, MS | 1 |
| Erwin, WD; Kornmehl, E; Leigh, B; Podoloff, DA; Sparks, RB; Spies, S; Stabin, MG; White, CA; Wiseman, GA; Witzig, T | 1 |
| Boerman, OC; Corstens, FH; Oyen, WJ; Postema, EJ | 1 |
| Goldsmith, SJ; Leonard, JP; Siegel, JA | 1 |
| Bartlett, NL; Erwin, WD; Grillo-López, AJ; Leigh, BR; Podoloff, DA; Schilder, RJ; Sparks, RB; Spies, SM; White, CA; Wiseman, GA; Witzig, TE | 1 |
| DeNardo, G; DeNardo, S; Goldstein, D; Hartmann Siantar, C; O'Donnell, R; Richman, C; Shen, S; Yuan, A | 1 |
| Dunn, WL; Leigh, BR; Stabin, MG; White, CA; Wiseman, GA | 1 |
| Alavi, A; Goldenberg, DM; Hartzell, KB; Klumpp, TR; Luger, SM; Maillard, I; Nasta, SD; Porter, DL; Schuster, SJ; Sharkey, RM; Stadtmauer, EA; Tsai, DE | 1 |
| Divgi, CR; Hamlin, PA; Larson, SM; Pandit-Taskar, N; Reyes, S | 1 |
| Emmanouilides, C | 1 |
| Boerman, OC; Buijs, WC; Oyen, WJ; Postema, EJ | 1 |
| Alavi, A; Brenner, A; Burton, J; Chatal, JF; Czuczman, MS; Goldenberg, DM; Hajjar, G; Kraeber-Bodere, F; Lamonica, D; Mahe, B; Mardirrosian, G; Matthies, A; Rogatko, A; Schuster, SJ; Sharkey, RM; Stadtmauer, EA; Toder, SP; Tsai, DE | 1 |
| Forero, A; Lobuglio, AF | 1 |
| Hernandez, MC; Knox, SJ | 1 |
| Witzig, TE | 1 |
| Gregory, SA | 1 |
| Gordon, LI | 1 |
| Horning, SJ | 1 |
| Borghaei, H; Schilder, RJ | 1 |
| Conti, PS | 1 |
| Spies, SM | 1 |
| Zhu, X | 1 |
| Britton, KE | 1 |
| Bischof Delaloye, A | 1 |
| Clayton, J | 1 |
| Koral, KF; Wahl, RL; Zasadny, K | 1 |
| Bartlett, NL; Blum, KA | 1 |
| Bartlett, N; Gordon, L; Molina, A; Murray, J; Schilder, R; Spies, S; Wang, H; White, C; Wiseman, G; Witzig, T | 1 |
| Evens, AM; Gordon, LI | 1 |
| Borghaei, H; Schilder, RJ; Wallace, SG | 1 |
| Winter, JN | 1 |
| Micallef, IN | 1 |
| Postema, EJ | 1 |
| Ansell, SM; Czuczman, MS; Emmanouilides, C; Gordon, LI; Molina, A; Pieslor, PC; Schilder, RJ; Theuer, C; Vo, K; Witzig, TE | 1 |
| Goldenberg, DM; Sharkey, RM | 1 |
| Marcus, R | 1 |
| Grillo-López, AJ | 1 |
| Hagenbeek, A; Lewington, V | 1 |
| Wiseman, GA; Witzig, TE | 1 |
| Anderson, AL; Dagis, A; Falk, P; Forman, S; Fung, H; Kirschbaum, M; Kogut, N; Krishnan, A; Kwok, C; Molina, A; Nademanee, A; Nakamura, R; O'donnell, M; Parker, P; Popplewell, L; Pullarkat, V; Raubitschek, A; Rodriguez, R; Sahebi, F; Smith, D; Smith, E; Snyder, D; Spielberger, R; Stein, A; White, C; Yamauchi, D; Zain, J | 1 |
| Cavallin-Ståhl, E; Goldenberg, DM; Hindorf, C; Horne, H; Lindén, O; Ohlsson, T; Stenberg, L; Strand, SE; Tennvall, J; Wegener, WA | 1 |
| Coleman, M; Furman, RR; Leonard, JP; Ruan, J | 1 |
| Akabani, G; Rao, AV; Rizzieri, DA | 1 |
| Avril, N; Jacobs, SA; Joyce, J; McCook, B; Torok, F; Vidnovic, N | 1 |
| Cheson, BD | 2 |
| de Nully Brown, P; Hansen, M; Jurlander, J; Lindén, O | 1 |
| Dierckx, RA; Otte, A | 1 |
| Aussie, J; Conti, PS; Foster, P; Molina, A; Pieslor, P; White, C | 1 |
| Leonard, JP | 1 |
| Balon, H; Brill, DR; Dillehay, GL; Ellerbroek, NA; Gaspar, LE; Grigsby, PW; Macklis, RM; Mauch, PM; Mian, TA; Potters, L; Silberstein, EB; Williams, TR; Wong, JC | 1 |
| Macklis, RM; Pohlman, B; Sweetenham, J | 1 |
| Darif, M; Emmanouilides, C; Flinn, IW; Gordon, LI; Molina, A; Schilder, RJ; Vo, K; Wiseman, GA; Witzig, TE | 1 |
| Bondly, C; Johnston, PB; Micallef, IN | 1 |
| Justice, TE; Martenson, JA; Wiseman, GA; Witzig, TE | 1 |
| Cheung, MC; Haynes, AE; Imrie, K; Meyer, RM; Stevens, A | 1 |
| Otte, A; Thompson, SL | 1 |
| Meredith, RF | 2 |
| Macklis, RM | 2 |
| DeNardo, GL; DeNardo, SJ; Sysko, VV | 1 |
| Ayala, E; Kharfan-Dabaja, MA; Raez, LE; Santos, ES | 1 |
| Du, Y; Frey, E; Prideaux, A; Sgouros, G; Song, H; Wahl, RL | 1 |
| Tobinai, K | 1 |
| Butrym, A; Jurczak, W; Mazur, G; Wróbel, T | 1 |
| Erba, P; Pauwels, EK | 1 |
| Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Matso, D; Vose, JM | 1 |
| Aliberti, G; Bavusi, S; Bombardieri, E; Botta, F; Chiesa, C; Coliva, A; Devizzi, L; Di Betta, E; Gianni, AM; Guidetti, A; Maccauro, M; Seregni, E | 1 |
| Czuczman, MS; Darif, M; Emmanouilides, C; Gordon, LI; Molina, A; Revell, S; Vo, K; Witzig, TE | 1 |
| Belanger, R; Doolittle, ND; Haluska, M; Hedrick, NA; Jahnke, K; Lacy, CA; Nance, RW; Neuwelt, EA; Ryan, DA; Tyson, RM; Varallyay, C | 1 |
| Adamson, PC; Angiolillo, A; Ayello, J; Cairo, MS; Cooney-Qualter, E; Fawwaz, RA; Harrison, L; Kohl, V; Krailo, M; Perkins, SL; vande Ven, C; Wiseman, G | 1 |
| Falk, P; Forman, SJ; Fung, HC; Krishnan, A; Molina, A; Nademanee, A; Palmer, JM; Raubitschek, AA; Rodriguez, R; Spielberger, RT; Yamauchi, D | 1 |
| Baccarani, M; Derenzini, E; Fanti, S; Fina, M; Musuraca, G; Perrotti, A; Stefoni, V; Tani, M; Vitolo, U; Zinzani, PL | 1 |
| Flinn, IW; Fung, H; Inwards, D; Krishnan, A; Molina, A; Nademanee, A; Winter, JN | 1 |
| Colletti, PM; Conti, PS; Ulaner, GA | 1 |
| Bodet-Milin, C; Campion, L; Dupas, B; Gastinne, T; Goldenberg, DM; Harousseau, JL; Huglo, D; Kraeber-Bodéré, F; Le Gouill, S; Morschhauser, F; Wegener, WA | 1 |
| Assié, K; Buvat, I; Dieudonné, A; Gardin, I; Tilly, H; Vera, P | 1 |
| Baccarani, M; Cabras, MG; De Luca, S; De Renzo, A; Derenzini, E; Fabbri, A; Fanti, S; Fattori, P; Fina, M; Gobbi, M; Guardigni, L; Marchi, E; Musuraca, G; Pellegrini, C; Perotti, A; Piccaluga, PP; Pileri, S; Pulsoni, A; Rigacci, L; Ronconi, S; Stefoni, V; Tani, M; Voso, MT; Zaccaria, A; Zinzani, PL | 1 |
| Friedberg, JW; Schaefer-Cutillo, J | 1 |
| Colcher, D | 1 |
| Anderson, DR; Chinn, PC; Hanna, N; Leonard, JE; Rosenberg, J | 1 |
| Angelberger, P; Bischof, C; Gludovacz, D; Hamilton, G; Kaserer, K; Kofler, A; Leimer, M; Pangerl, T; Peck-Radosavljevic, M; Schlangbauer-Wadl, H; Smith-Jones, PM; Traub, T; Virgolini, I | 1 |
| Emmanouilides, C; Gordon, LI; Grillo-López, AJ; Gutheil, J; Janakiraman, N; Raubitschek, A; Schilder, RJ; Silverman, DH; Spies, S; White, CA; Wiseman, GA; Witzig, TE | 1 |
| Alavi, A; Goldenberg, DM; Hajjar, G; Juweid, ME; Luger, S; Sharkey, RM; Stadtmauer, E; Suleiman, S; Swayne, LC | 1 |
| Emmanouilides, C; Gordon, LI; Grillo-López, AJ; Gutheil, J; Janakiraman, N; Parker, E; Raubitschek, A; Schilder, RJ; Silverman, DH; Spies, S; White, CA; Wiseman, GA; Witzig, TE | 1 |
| Appelbaum, JW; Axworthy, D; Breitz, HB; Bryan, JK; Fisher, D; Gaffigan, S; Press, O; Reno, J; Stone, D; Weiden, PL | 1 |
| DeNardo, GL; DeNardo, SJ; Kroger, LA; Kukis, DL; Meares, CF; O'Donnell, RT; Shen, S; Yuan, A | 1 |
| Christensen, SD; DeNardo, DA; DeNardo, GL; Goldstein, DS; Kroger, LA; Kukis, DL; Leigh, BR; O'Donnell, RT; Shen, S; Yuan, A | 1 |
| Belanger, R; Berlfein, JR; Dahlbom, M; Ding, E; Dunn, WL; Erwin, W; Grillo-López, AJ; Karvelis, K; Raubitschek, A; Schultheiss, T; Silverman, DH; Spies, S; Stabin, M; White, CA; Wiseman, GA; Witzig, TE | 1 |
| Eckersberg-Rhodes, TE; Erwin, WD; Groch, MW; Kelly, ME; Nannapaneni, M; Rao, P; Spies, SM | 1 |
| DeNardo, GL; DeNardo, SJ; Kukis, DL; Meares, CF; Mirick, GR; O'Donnell, RT; Shen, S | 1 |
| DeNardo, GL; DeNardo, SJ; Goldstein, DS; Kroger, LA; Kukis, DL; Meares, CF; O'Donnell, RT; Shen, S | 1 |
| Joyce, RM; Krasner, C | 1 |
| Cripe, L; Czuczman, MS; Emmanouilides, C; Emmanuolides, C; Flinn, IW; Gordon, LI; Grillo-López, AJ; Olejnik, T; Saleh, M; Silverman, DH; Spies, SS; White, CA; Wiseman, GA; Witzig, TE | 1 |
| Conti, PS; Fink-Bennett, DM; Lamonica, DM; Marcus, CS; Nabi, HA; Nagle, CE; Wagner, HN; Wiseman, GA | 1 |
| Crawford, LM | 1 |
| Knight, N | 1 |
| Bartlett, NL; Cabanillas, F; Czuczman, MS; Emmanouilides, C; Gordon, LI; Grillo-López, AJ; Joyce, R; Multani, P; Padre, N; Pohlman, BL; White, CA; Wiseman, GA; Witzig, TE | 1 |
| Allen, RS; Bartlett, NL; Gordon, LI; Grillo-López, AJ; Multani, PS; Murray, JL; Saleh, M; Schilder, RJ; Spies, S; White, CA; Wiseman, GA; Witzig, TE | 1 |
49 review(s) available for yttrium radioisotopes and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting.
Topics: Antigens, CD20; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Radioimmunotherapy; Tissue Distribution; Yttrium Radioisotopes | 2022 |
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update.
Topics: Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2023 |
Perspectives on metals-based radioimmunotherapy (RIT): moving forward.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents, Immunological; Chelating Agents; Click Chemistry; Clinical Trials as Topic; Dose Fractionation, Radiation; Drug Delivery Systems; Forecasting; Humans; Immunoglobulin Fab Fragments; Lymphoma, Non-Hodgkin; Mice; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms, Experimental; Organ Specificity; Precision Medicine; Radiation Tolerance; Radioimmunotherapy; Radiopharmaceuticals; Receptor Protein-Tyrosine Kinases; Single-Chain Antibodies; Single-Domain Antibodies; Yttrium Radioisotopes | 2021 |
Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
Topics: Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Humans; Immunoconjugates; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Neoplasms; Radioimmunotherapy; Yttrium Radioisotopes | 2014 |
Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Humans; Immunotoxins; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2009 |
Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Transplantation Conditioning; Yttrium Radioisotopes | 2009 |
New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary.
Topics: Antibodies, Monoclonal; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2009 |
Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009).
Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Clinical Trials as Topic; Embolization, Therapeutic; Humans; Liver Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Neuroendocrine Tumors; Radioimmunotherapy; Receptors, Peptide; Treatment Outcome; Yttrium Radioisotopes | 2011 |
Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma.
Topics: Biological Availability; Half-Life; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2003 |
Radioimmunotherapy for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Immunoconjugates; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2003 |
History of antibody therapy for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; History, 19th Century; History, 20th Century; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2003 |
Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).
Topics: Antibodies, Monoclonal; Antigens, CD20; Antigens, Neoplasm; Apoptosis; Cell Cycle; Dose-Response Relationship, Radiation; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2003 |
Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Recurrence; Risk Factors; Thrombocytopenia; Yttrium Radioisotopes | 2003 |
Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin).
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neutropenia; Patient Selection; Thrombocytopenia; Yttrium Radioisotopes | 2003 |
Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Patient Care Team; Patient Selection; Radioimmunotherapy; Safety; Yttrium Radioisotopes | 2003 |
Future directions in radioimmunotherapy for B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2003 |
Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Topics: Antibodies, Monoclonal; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Safety; Yttrium Radioisotopes | 2004 |
Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Topics: Antibodies, Monoclonal; Diagnostic Imaging; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiotherapy Dosage; Tissue Distribution; Yttrium Radioisotopes | 2004 |
Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin).
Topics: Antibodies, Monoclonal; Humans; Lymphoma, Non-Hodgkin; Radiation Protection; Radioimmunotherapy; Universal Precautions; Yttrium Radioisotopes | 2004 |
The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
Topics: Antibodies, Monoclonal; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Nuclear Medicine; Radioimmunotherapy; Yttrium Radioisotopes | 2003 |
Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.
Topics: Antibodies, Monoclonal; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiotherapy Dosage; Treatment Outcome; Yttrium Radioisotopes | 2003 |
Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy.
Topics: Antibodies, Monoclonal; Humans; Lymphoma, Non-Hodgkin; Oncology Nursing; Primary Nursing; Radioimmunotherapy; Yttrium Radioisotopes | 2003 |
90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.
Topics: Animals; Antibodies, Monoclonal; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Forecasting; Humans; Immunoconjugates; Lymphoma, Non-Hodgkin; Mice; Neutropenia; Radioimmunotherapy; Radiotherapy Dosage; Thrombocytopenia; Treatment Outcome; Yttrium Radioisotopes | 2004 |
Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond.
Topics: Antibodies, Monoclonal; Antigens, CD20; Clinical Trials as Topic; Dose-Response Relationship, Radiation; Humans; Lymphoma, Non-Hodgkin; Quality of Life; Radioimmunotherapy; Yttrium Radioisotopes | 2004 |
Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Lymphoma, Non-Hodgkin; Neoplasms, Second Primary; Prognosis; Radioimmunotherapy; Risk Factors; Treatment Outcome; Yttrium Radioisotopes | 2004 |
Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Stem Cell Transplantation; Transplantation, Autologous; Yttrium Radioisotopes | 2004 |
Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Stem Cell Transplantation; Survival Analysis; Yttrium Radioisotopes | 2004 |
Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.
Topics: Antibodies, Monoclonal; Combined Modality Therapy; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2004 |
Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma.
Topics: Antibodies, Monoclonal; Europe; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Neoplasm Staging; Patient Selection; Practice Guidelines as Topic; Radioimmunotherapy; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Yttrium Radioisotopes | 2005 |
New developments in immunotherapy for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Humans; Immunotherapy; Interleukin-2; Lymphoma; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2005 |
Radioimmunotherapy for Non-Hodgkin's Lymphoma.
Topics: Antibodies, Monoclonal; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2005 |
The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2005 |
Review of clinical radioimmunotherapy.
Topics: Antibodies, Monoclonal; Antibody Formation; Antigens, CD20; Antineoplastic Agents; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Neoplasms; Radioimmunotherapy; Radiometry; Stem Cell Transplantation; Transplantation, Autologous; Yttrium Radioisotopes | 2006 |
Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Clinical Trials as Topic; Drug Approval; Humans; Lymphoma, Non-Hodgkin; Patient Selection; Yttrium Radioisotopes | 2006 |
Yttrium 90 ibritumomab tiuxetan in lymphoma.
Topics: Antibodies, Monoclonal; Clinical Trials as Topic; Disease Progression; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Quality of Life; Radioimmunotherapy; Radiometry; Treatment Outcome; Yttrium Radioisotopes | 2006 |
Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2006 |
Logistics of therapy with the ibritumomab tiuxetan regimen.
Topics: Antibodies, Monoclonal; Antigens, CD20; Drug Administration Schedule; Health Physics; Humans; Licensure, Hospital; Lymphoma, Non-Hodgkin; Patient Care Team; Patient Selection; Radiation Protection; Radioimmunotherapy; Yttrium Radioisotopes | 2006 |
Cure of incurable lymphoma.
Topics: Antibodies, Monoclonal; Clinical Trials, Phase III as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes | 2006 |
Radioimmunotherapy of non-Hodgkin's lymphomas.
Topics: Animals; Antibodies, Monoclonal; Humans; Immunoconjugates; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2006 |
Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiometry; Recurrence; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2006 |
[New trends in non-Hodgkin's lymphoma therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Protease Inhibitors; Radioimmunotherapy; Yttrium Radioisotopes | 2006 |
Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents.
Topics: Animals; Antibodies, Monoclonal; Humans; Immunoconjugates; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiopharmaceuticals; Yttrium Radioisotopes | 2007 |
Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy Dosage; Remission Induction; Treatment Outcome; Yttrium Radioisotopes | 2007 |
Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Transplantation Conditioning; Yttrium Radioisotopes | 2007 |
Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lymphoma, Non-Hodgkin; Myeloid Cells; Radioimmunotherapy; Radiotherapy Dosage; Rituximab; Salvage Therapy; Yttrium Radioisotopes | 2008 |
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Lymphoma, Non-Hodgkin; Pentetic Acid; Radioimmunotherapy; Recurrence; Yttrium Radioisotopes | 1999 |
Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Yttrium Radioisotopes | 2001 |
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Clinical Trials as Topic; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Quality of Life; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes | 2002 |
Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiotherapy Dosage; Yttrium Radioisotopes | 2002 |
37 trial(s) available for yttrium radioisotopes and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Invasiveness; Podophyllotoxin; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2018 |
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radioimmunotherapy; Salvage Therapy; Survival Rate; Tissue Distribution; Yttrium Radioisotopes | 2013 |
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; B-Lymphocytes; Drug Administration Schedule; Humans; Immunologic Factors; Interleukin-10; Interleukin-1beta; Lymphoma, Non-Hodgkin; Male; Middle Aged; Oligodeoxyribonucleotides; Radioimmunotherapy; Radiopharmaceuticals; Recurrence; Survival Analysis; Tumor Necrosis Factor-alpha; Yttrium Radioisotopes | 2013 |
Rituximab maintenance versus radio-immunotherapy consolidation in first remission follicular non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiopharmaceuticals; Rituximab; Yttrium Radioisotopes | 2013 |
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Marrow; Disease Progression; Female; Humans; Indium Radioisotopes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Radioimmunotherapy; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2014 |
In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Cell Line; Chelating Agents; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Lutetium; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mice; Pilot Projects; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Rituximab; Yttrium Radioisotopes | 2009 |
Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Prednisone; Radioimmunotherapy; Rituximab; Treatment Outcome; Vincristine; Yttrium Radioisotopes | 2009 |
The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Metalloporphyrins; Middle Aged; Porphyrins; Radiation-Sensitizing Agents; Radioimmunotherapy; Recurrence; Treatment Outcome; Yttrium Radioisotopes | 2009 |
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.
Topics: Adult; Aged; Antibodies, Monoclonal; Combined Modality Therapy; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Yttrium Radioisotopes | 2010 |
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2010 |
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Bone Marrow; Female; Follow-Up Studies; Granulocyte-Macrophage Progenitor Cells; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Radioimmunotherapy; Risk; Telomere; Yttrium Radioisotopes | 2011 |
Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Dose-Response Relationship, Radiation; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Grading; Prognosis; Prospective Studies; Radioimmunotherapy; Radiopharmaceuticals; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Yttrium Radioisotopes | 2012 |
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Pyrazines; Radioimmunotherapy; Recurrence; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Rituximab; Treatment Outcome; Yttrium Radioisotopes | 2002 |
Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Bone Marrow; Half-Life; Humans; Immunoconjugates; Indium Radioisotopes; Kidney; Lymphoma, Non-Hodgkin; Middle Aged; Radiation Dosage; Radioimmunotherapy; Radiotherapy Dosage; Recurrence; Rituximab; Tissue Distribution; Yttrium Radioisotopes | 2003 |
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
Topics: Adolescent; Antibodies, Monoclonal; Antigens, CD20; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiometry; Salvage Therapy; Thrombocytopenia; Tissue Distribution; Tomography, Emission-Computed; Treatment Outcome; Yttrium Radioisotopes | 2003 |
Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Humans; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Prospective Studies; Radioimmunotherapy; Rituximab; Salvage Therapy; Tissue Distribution; Tomography, Emission-Computed; Treatment Outcome; Yttrium Radioisotopes | 2003 |
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Female; Heterocyclic Compounds, 1-Ring; Humans; Indium; Isotopes; Lymphoma, Non-Hodgkin; Male; Metabolic Clearance Rate; Middle Aged; Predictive Value of Tests; Prognosis; Radioimmunotherapy; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy; Radiotherapy Dosage; Tissue Distribution; Treatment Outcome; Yttrium Radioisotopes | 2003 |
Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD20; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Thrombocytopenia; Yttrium Radioisotopes | 2004 |
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.
Topics: Adult; Antibodies, Monoclonal; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radioimmunotherapy; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Yttrium Radioisotopes | 2005 |
Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Cell Adhesion Molecules; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Infusions, Intravenous; Lectins; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Yttrium Radioisotopes | 2005 |
Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antigens, CD20; Blood Platelets; Clinical Trials as Topic; Female; Fluorodeoxyglucose F18; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Middle Aged; Platelet Count; Pleural Effusion; Positron-Emission Tomography; Radioimmunotherapy; Recurrence; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2005 |
4. Antibody therapy for malignant lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2007 |
Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Stem Cell Transplantation; Transplantation, Autologous; Yttrium Radioisotopes | 2007 |
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.
Topics: Antibodies, Monoclonal; Dose-Response Relationship, Radiation; Humans; Lymphoma, Non-Hodgkin; Myeloablative Agonists; Radioimmunotherapy; Yttrium Radioisotopes | 2007 |
A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Bone Marrow; Child; Child, Preschool; Female; Humans; Immunoconjugates; Indium Radioisotopes; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Radiation Dosage; Radioimmunotherapy; Radiotherapy Dosage; Rituximab; Tissue Distribution; Yttrium Radioisotopes | 2007 |
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Radioimmunotherapy; Stem Cell Transplantation; Treatment Outcome; Yttrium Radioisotopes | 2008 |
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Radioimmunotherapy; Survival Analysis; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2008 |
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Disease Progression; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Radioimmunotherapy; Radiopharmaceuticals; Salvage Therapy; Sensitivity and Specificity; Sialic Acid Binding Ig-like Lectin 2; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2008 |
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Italy; Kaplan-Meier Estimate; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Probability; Radioimmunotherapy; Risk Assessment; Survival Analysis; Vidarabine; Yttrium Radioisotopes | 2008 |
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Recurrence; Rituximab; Yttrium Radioisotopes | 1999 |
Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
Topics: Adult; Antigens, CD20; Biotin; Female; Humans; Immunoglobulin G; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Radioimmunotherapy; Radionuclide Imaging; Radiopharmaceuticals; Recombinant Fusion Proteins; Tissue Distribution; Yttrium Radioisotopes | 2000 |
Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.
Topics: Adult; Antibodies, Monoclonal; Humans; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Radiation Dosage; Radiation Tolerance; Radioimmunotherapy; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution; Yttrium Radioisotopes | 1999 |
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bone Marrow; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiometry; Rituximab; Yttrium Radioisotopes | 2000 |
Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin's B-cell lymphoma.
Topics: Algorithms; Antibodies, Monoclonal; Antigens, CD20; Blood Cell Count; Bone Marrow; Bone Marrow Diseases; Humans; Lymphoma, Non-Hodgkin; Predictive Value of Tests; Radioimmunotherapy; Radiometry; Spine; Yttrium Radioisotopes | 2001 |
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD19; Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Progression; Disease-Free Survival; Female; Humans; Liver; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Radionuclide Imaging; Rituximab; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2002 |
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radiation Dosage; Radioimmunotherapy; Remission Induction; Salvage Therapy; Thrombocytopenia; Tissue Distribution; Treatment Outcome; Yttrium Radioisotopes | 2002 |
59 other study(ies) available for yttrium radioisotopes and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study.
Topics: Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Radioimmunotherapy; Retrospective Studies; Yttrium Radioisotopes | 2023 |
Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2023 |
Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Induction Chemotherapy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Rituximab; Treatment Outcome; Yttrium Radioisotopes | 2019 |
Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antigens, CD20; Cell Line, Tumor; Dendrimers; Drug Delivery Systems; Humans; Immunoconjugates; Lymphoma, Non-Hodgkin; Mice; Nanomedicine; Radioimmunotherapy; Radiopharmaceuticals; Tissue Distribution; Yttrium Radioisotopes | 2018 |
Theranostics in Hematooncology.
Topics: Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Positron Emission Tomography Computed Tomography; Precision Medicine; Radioimmunotherapy; Yttrium Radioisotopes | 2023 |
Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy.
Topics: Antibodies, Monoclonal; Diagnostic Imaging; Lymphoma, Non-Hodgkin; Positron-Emission Tomography; Predictive Value of Tests; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2019 |
Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.
Topics: Antibodies, Monoclonal; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiopharmaceuticals; Risk Factors; Transplantation, Autologous; Yttrium Radioisotopes | 2013 |
Development of anthropomorphic hand phantoms for personal dosimetry in 90Y-Zevalin preparation and patient delivering.
Topics: Anthropometry; Antibodies, Monoclonal; Calibration; Hand; Humans; Lymphoma, Non-Hodgkin; Phantoms, Imaging; Radiation Dosage; Radiation Protection; Radioimmunotherapy; Radiometry; Thermoluminescent Dosimetry; Tissue Distribution; Yttrium Radioisotopes | 2014 |
Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Cell Line, Tumor; Drug Compounding; Freeze Drying; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Indium Radioisotopes; Isotope Labeling; Lymphoma, Non-Hodgkin; Male; Radioimmunotherapy; Radionuclide Imaging; Rats; Rituximab; Serum Albumin; Tissue Distribution; Yttrium Radioisotopes | 2014 |
Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Follow-Up Studies; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Does health economics have an impact on non-Hodgkin's lymphoma patients' options?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiopharmaceuticals; Yttrium Radioisotopes | 2008 |
The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: two cases of abnormal biodistribution.
Topics: Aged; Antibodies, Monoclonal; Female; Humans; Indium Radioisotopes; Lymphoma, Non-Hodgkin; Middle Aged; Radioimmunotherapy; Radiometry; Yttrium Radioisotopes | 2009 |
Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Disease Progression; Disease-Free Survival; Humans; Immunotoxins; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2009 |
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Combined Modality Therapy; Humans; Image Processing, Computer-Assisted; Indium Radioisotopes; Isotope Labeling; Lymphoma, Non-Hodgkin; Organ Size; Positron-Emission Tomography; Radiometry; Radiopharmaceuticals; Rituximab; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2010 |
Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Bone Marrow; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Leukocyte Count; Linear Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Models, Statistical; Neutrophils; Platelet Count; Predictive Value of Tests; Radioimmunotherapy; Radiometry; Radiopharmaceuticals; Thrombocytopenia; Yttrium Radioisotopes | 2010 |
Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods.
Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Humans; Imaging, Three-Dimensional; Iodine Radioisotopes; Liver Neoplasms; Lutetium; Lymphoma, Non-Hodgkin; Microspheres; Models, Statistical; Monte Carlo Method; Neuroendocrine Tumors; Radioisotopes; Radiometry; Radionuclide Imaging; Radiotherapy Dosage; Yttrium Radioisotopes | 2013 |
Quantification of dose nonuniformities by voxel-based dosimetry in patients receiving 90Y-ibritumomab-tiuxetan.
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Grading; Radionuclide Imaging; Radiotherapy Dosage; Tissue Distribution; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Radioimmunotherapy; Retrospective Studies; Salvage Therapy; Treatment Outcome; Yttrium Radioisotopes | 2002 |
Pretargeted radioimmunotherapy (PRIT) using an antibody-streptavidin fusion protein in non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Neoplasm; Biotin; Female; Humans; Immunoconjugates; Indium Radioisotopes; Lymphoma, Non-Hodgkin; Middle Aged; Radioimmunotherapy; Recombinant Fusion Proteins; Rhenium; Streptavidin; Tissue Distribution; Yttrium Radioisotopes | 2002 |
Ibritumomab tiuxetan (Zevalin) for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Drug Administration Schedule; Fees, Pharmaceutical; Half-Life; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Randomized Controlled Trials as Topic; Tachycardia; Yttrium Radioisotopes | 2002 |
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Stability; Female; Heterocyclic Compounds, 1-Ring; Humans; In Vitro Techniques; Isotope Labeling; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pentetic Acid; Radioimmunotherapy; Radiopharmaceuticals; Reference Values; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes | 2003 |
Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antigens, CD20; Chromosomes, Human, Pair 11; DNA-Binding Proteins; Female; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; Immunoconjugates; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Proto-Oncogenes; Radioimmunotherapy; Transcription Factors; Yttrium Radioisotopes | 2002 |
Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody.
Topics: Antibodies, Monoclonal; Antigens, CD20; Guidelines as Topic; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2003 |
Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.
Topics: Adult; Aged; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Female; Humans; Image Processing, Computer-Assisted; Indium Radioisotopes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Radiotherapy Dosage; Research Design; Tissue Distribution; Yttrium Radioisotopes | 2003 |
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, CD20; Antigens, Differentiation, B-Lymphocyte; B-Lymphocytes; Cell Adhesion Molecules; Disease Progression; Humans; Lectins; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Radioimmunotherapy; Radiopharmaceuticals; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Yttrium Radioisotopes | 2003 |
New strategies in radioimmunotherapy for lymphoma.
Topics: Antibodies, Monoclonal; Clinical Trials, Phase III as Topic; Contraindications; Humans; Iodine Radioisotopes; Lymphoma; Lymphoma, Non-Hodgkin; Radiometry; Yttrium Radioisotopes | 2003 |
Underestimation of absorbed dose to kidney.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Humans; Kidney; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Recurrence, Local; Radiation Dosage; Radioimmunotherapy; Radiotherapy Dosage; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution; Yttrium Radioisotopes | 2003 |
Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician.
Topics: Antibodies, Monoclonal; Humans; Lymphoma, Non-Hodgkin; Nuclear Medicine; Physician's Role; Radioimmunotherapy; Yttrium Radioisotopes | 2004 |
Radioimmunotherapy of Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2004 |
Bias reduction in correlation of radiation-absorbed dose with response.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Female; Humans; Lymphoma, Non-Hodgkin; Male; Metabolic Clearance Rate; Middle Aged; Predictive Value of Tests; Prognosis; Radioimmunotherapy; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Reproducibility of Results; Selection Bias; Sensitivity and Specificity; Tissue Distribution; Treatment Outcome; Yttrium Radioisotopes | 2004 |
Dosimetry and radioimmunotherapy of non-Hodgkin's lymphoma.
Topics: Humans; Lymphoma, Non-Hodgkin; Radiation Dosage; Radioimmunotherapy; Yttrium Radioisotopes | 2004 |
Radioimmunotherapy of non-Hodgkin's lymphoma revisited.
Topics: Antibodies, Monoclonal; Clinical Trials as Topic; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2005 |
Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Combined Modality Therapy; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiopharmaceuticals; Yttrium Radioisotopes | 2005 |
90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Lymphoma, Non-Hodgkin; Patient Selection; Radioimmunotherapy; Radiopharmaceuticals; Risk Assessment; Yttrium Radioisotopes | 2005 |
Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD20; Disease Progression; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2005 |
[Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 2005 |
Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk?
Topics: Alkylating Agents; Antibodies, Monoclonal; Humans; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Prognosis; Radioimmunotherapy; Risk; Time Factors; Yttrium Radioisotopes | 2005 |
The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry.
Topics: Antibodies, Monoclonal; Humans; Indium Radioisotopes; Lymphoma, Non-Hodgkin; Organ Specificity; Radionuclide Imaging; Radiopharmaceuticals; Registries; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Tissue Distribution; United States; Whole Body Imaging; Whole-Body Counting; Yttrium Radioisotopes | 2005 |
Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Cytotoxicity Tests, Immunologic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Iodine Radioisotopes; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2005 |
Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources.
Topics: Antibodies, Monoclonal; Ascites; Bone Neoplasms; Chromium Compounds; Humans; Hyperthyroidism; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Organometallic Compounds; Organophosphorus Compounds; Pain; Patient Isolation; Phosphates; Pleural Effusion, Malignant; Polycythemia Vera; Radiation Protection; Radiopharmaceuticals; Sodium Iodide; Strontium Radioisotopes; Thrombocytopenia; Thyroid Neoplasms; Yttrium Radioisotopes | 2006 |
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Radiopharmaceuticals; Recurrence; Remission Induction; Yttrium Radioisotopes | 2006 |
Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes | 2006 |
90Y-Ibritumomab tiuxetan: new drug, interesting concept, and encouraging in practice.
Topics: Antibodies, Monoclonal; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Practice Patterns, Physicians'; Prognosis; Radiopharmaceuticals; Treatment Outcome; Yttrium Radioisotopes | 2006 |
Practical and clinical benefits of radioimmunotherapy lead to advantages in cost-effectiveness in the treatment of patients with non-Hodgkin's lymphoma.
Topics: Cost-Benefit Analysis; Humans; Insurance, Health; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Safety; Treatment Outcome; Yttrium Radioisotopes | 2006 |
Radioimmunotherapy in a radiation oncology environment: building a multi-specialty team.
Topics: Antibodies, Monoclonal; Humans; Interprofessional Relations; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Medical Oncology; Patient Care Team; Radiation Oncology; Radioimmunotherapy; Yttrium Radioisotopes | 2006 |
Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
Topics: Adult; Antigens, CD20; Humans; Iodine Radioisotopes; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Monte Carlo Method; Neoplasm Metastasis; Phantoms, Imaging; Radioimmunotherapy; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Software; Yttrium Radioisotopes | 2007 |
Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2007 |
Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Blood-Brain Barrier; Brain Neoplasms; Carboplatin; Combined Modality Therapy; Female; Humans; Indium Radioisotopes; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Radioimmunotherapy; Yttrium Radioisotopes | 2007 |
B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Humans; Image Processing, Computer-Assisted; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Positron-Emission Tomography; Radioimmunotherapy; Retrospective Studies; Tomography, Spiral Computed; Treatment Outcome; Yttrium Radioisotopes | 2008 |
Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Radiation; Female; Humans; Imaging, Three-Dimensional; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Radiometry; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes | 2008 |
Centralized radiolabeling of antibodies for radioimmunotherapy.
Topics: Antigens, CD20; Humans; Iodine Radioisotopes; Isotope Labeling; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Yttrium Radioisotopes | 1998 |
Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antigens, CD20; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, Inbred BALB C; Radioimmunotherapy; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes | 1999 |
DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoid Tumor; Cell Membrane; Colonic Neoplasms; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasms; Pancreatic Neoplasms; Peptides, Cyclic; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Thyroid Neoplasms; Tissue Distribution; Tumor Cells, Cultured; Yttrium Radioisotopes | 1999 |
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Cell Adhesion Molecules; Female; Humans; Indium Radioisotopes; Iodine Radioisotopes; Lectins; Lymphoma, Non-Hodgkin; Male; Mice; Middle Aged; Radioimmunotherapy; Radiotherapy Dosage; Recurrence; Sialic Acid Binding Ig-like Lectin 2; Yttrium Radioisotopes | 1999 |
Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Humans; Indium Radioisotopes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Radiotherapy Dosage; Yttrium Radioisotopes | 2000 |
Metabolite production in patients with lymphoma after radiometal-labeled antibody administration.
Topics: Adult; Aged; Antibodies, Monoclonal; Chromatography, High Pressure Liquid; Female; Humans; Indium Radioisotopes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Radiotherapy Dosage; Yttrium Radioisotopes | 2001 |
Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Copper Radioisotopes; Female; Heterocyclic Compounds; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Male; Metabolic Clearance Rate; Middle Aged; Organometallic Compounds; Radioimmunotherapy; Radiotherapy Dosage; Yttrium Radioisotopes | 2000 |
From the Food and Drug Administration.
Topics: Adolescent; Antibodies, Monoclonal; Anticholesteremic Agents; Antineoplastic Agents; Humans; Hyperlipoproteinemia Type II; Indium Radioisotopes; Lovastatin; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiopharmaceuticals; United States; United States Food and Drug Administration; Yttrium Radioisotopes | 2002 |
Radioimmunotherapy and NHL: nuclear medicine on the oncology team.
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Drug Approval; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; United States; United States Food and Drug Administration; Yttrium Radioisotopes | 2002 |